Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
Optimal Dose of ACE Inhibitor for Treatment of Diabetic Nephropathy in Type 1 Diabetic Patients With Hypertension and Diabetic Nephropathy
Sponsor: Steno Diabetes Center Copenhagen
Listed as NCT00118976, this NA trial focuses on Diabetes Mellitus, Type I and Diabetic Nephropathy and remains completed. Sponsored by Steno Diabetes Center Copenhagen, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 3 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Jun 2019 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Mar 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Steno Diabetes Center Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .